Hanyu Pharmaceutical announced on August 12 that since the company's phase III clinical trials of the company's simeglutide injection have been completed, the simeglutide injection has cooperated with Sansheng Mandi and the joint CDE application has been accepted. Recently, the company and Sansheng Mandy signed the “Simeglutide Injection - Blood Sugar Control Cooperation Agreement for Adult Type 2 Diabetics” and a “Commissioned Production and Supply Agreement”. The two sides reached cooperation on the development, registration, production and commercialization of simeglutide injections in the Chinese region.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.